Abstract – In the recent years, the health effects of fish (and n-3 fatty acids) have attracted considerable scientific interest. The present consensus is that the cardioprotection of very long chain n-3 fatty acids (also called EPA and DHA) at the low dosage used in recent secondary prevention trials primarily results from an effect on the ischemic myocardium and probably not from an effect on blood lipids and hemostasis. In other words, at these low dosages, there is apparently no major effect of these fatty acids on the progression of the vascular atherosclerotic lesions. In contrast, dietary alpha-linolenic acid (ALA), the parent compound of the very long chain n-3 fatty acids occurring in some vegetable oils, may be protective through mechanisms other than the myocardial (anti-arrhythmic) ones. In addition to its own direct preventive effect on cardiac arrhythmias, dietary ALA actually inhibits the elongation and desaturation of linoleic acid (18:2 n-6) into arachidonic acid. Because arachidonic acid (20:4 n-6) plays an important role in inflammation (as the precursor of the proinflammatory eicosanoids and leukotrienes), modifying its amount in blood and cell membranes influences the prevalence and severity of eicosanoid-related disorders, including atherosclerotic complications. The present knowledge of n-3 fatty acids justifies that physicians, in particular cardiologists in the context of secondary prevention of coronary heart disease, manage their patients, the young and the old, to increase their consumption of these fatty acids. They can only advise them to adequately adapt their diet (for instance in primary prevention), but in most cases, the systematic prescription of capsules containing oils enriched in ALA and EPA + DHA will be, ethically and scientifically, an obligation.

coronary heart disease / dietary fatty acids / fish / inflammation / sudden cardiac death / atherosclerosis / nutrition
of fish intake [2]; (2) the different mixes of fish types in the diet, for instance fatty fish versus lean fish, as well as different geographic origins of the fish [5]; (3) the potential contamination of fish by toxic heavy metals in certain areas [6]; (4) a possible bias due to CHD patients (or subjects at high risk of CHD) being aware that fish consumption is cardioprotective, which may result in a reversal of the fish eating-CHD relationship from “cause-effect” to “effect-cause” [2, 3]; (5) differences in the methods used to validate and classify CHD endpoints, with only a few studies reporting, for instance, on both sudden and non-sudden cardiac death; (6) differences in risk levels among different populations, with data suggesting that fish consumption is not associated with a decrease in CHD mortality in low-risk populations whereas it is associated with a markedly reduced CHD mortality in high-risk populations [7]. The last possibility is very simply that the effect of fish and seafood may vary with the amount consumed or, in other words, with the quantity of n-3 fatty acids (the main fatty acids in these foodstuffs) in the diet in relation with the other, saturated and unsaturated, fatty acids.

When assessing more precisely (whenever possible) the cause of cardiac death, however, the epidemiological data suggest that the benefit of eating fish primarily lies in a reduction of sudden cardiac death (SCD). A case-control study in Seattle [8] and a prospective study among US physicians [9] indicate that a modest fish intake may be associated with a 50% decrease in the risk of SCD but no decrease in the risk of non-sudden cardiac death or myocardial infarction [9]. Moreover, the use of biomarkers (the concentrations of n-3 fatty acids) in blood or cells totally confirms the results of studies using the evaluation of dietary intakes [10].

Stronger evidence of an effect of the longchain n-3 fatty acids (Fig. 1), which are relatively abundant in fatty fish (docosahexaenoic [DHA] and eicosapentanoic [EPA] acids), on SCD came from laboratory and clinical research indicating that these fatty acids have potent anti-arrhythmic properties, as summarized in a recent article [11]. Alexander Leaf’s team, for instance, described the electrophysiological effects of these fatty acids in cultured cardiac myocytes as well as their antiarrhythmic effects in laboratory animals [12]. Billman et al. showed that in a dog model initially used to elucidate the role of the autonomic nervous system on ischemic ventricular fibrillation, intravenous administration of n-3 fatty acids prevented SCD during myocardial ischemia [13]. Christensen et al. reported a randomized trial investigating the effect of longchain n-3 fatty acids on heart rate variability in patients with recent acute myocardial infarction and a low left ventricular ejection fraction [14]. High heart rate variability is thought to reflect high baroreflex sensitivity and has been clearly associated with good outcomes in patients having survived a recent acute coronary event [15]. Christensen et al. have found a positive correlation between n-3 fatty acids in the diet (and blood) and baroreflex sensitivity in their CHD patients [14]. In another study, they showed that the intake of n-3 fatty acids is associated with an increased heart rate variability in a dose-dependent manner [16]. The preventive effect of n-3 fatty acids on the risk of SCD is therefore presumably partly related to an anti-arrhythmic effect due to a favorable shift in the vagal/sympathetic balance, an effect known to decrease the susceptibility to ventricular arrhythmias [17]. In addition to an effect on cardiac ion channels [11] and heart rate variability [17], n-3 fatty acids may protect the heart through a third mechanism called preconditioning. In animal models of myocardial ischemia, dietary fish oil supplementation has been shown to significantly reduce infarct size [18], indicating that the myocardium, whose cells are rich in n-3 fatty acids, is resistant to ischemia. It is likely that this ability to resist to ischemia results from a direct effect of n-3 fatty acids on energy metabolism [19].
relative importance of the effect on cardiac ion channels, on the autonomic nervous system, on the preconditioning phenomenon, or even on the local production of pro-arrhythmic and anti-arrhythmic eicosanoids), there is now a large consensus to say that n-3 fatty acids have an important cardioprotective effect in patients with established CHD and that cardiologists should recommend a minimum amount of fish in the diet of their patients [20, 21]. In contrast, large amounts have not been shown to be cardioprotective. This is a very important point when considering strategies to prevent CHD. The consensus is also that the cardioprotection of long chain n-3 fatty acids at the low dosage used in the trials primarily results from an effect on the ischemic myocardium and probably not from an effect on blood lipids and hemostasis. In others words, at these low dosages, there is apparently no major effect on the progression of the vascular lesions. In contrast, dietary alpha-linolenic acid (ALA), the parent compound of the long chain n-3 fatty acids (Fig. 1) occurring in some vegetable oils, may be protective through mechanisms other than the myocardial ones (see below).

Indeed, for those who cannot (or will not) eat fish or other seafoods rich in long

**Figure 1.** The desaturation and elongation pathway of the n-3 fatty acids, departing from the essential alpha-linolenic acid (ALA) found in some natural vegetable foods, such as walnut and canola oil. Note that, in competition with arachidonic acid, EPA is the starting point for the synthesis of prostaglandins and eicosanoids (see text). Increasing the intake of EPA and DHA, through increased consumption of marine foods, and increasing the intake of ALA are therefore two different preventive strategies in cardiology.
chain n-3 fatty acids, a less direct route to obtain the desirable levels of these fatty acids in their plasma and their cell (in particular cardiac cell) membrane is an increased consumption of ALA (Fig. 1). In addition to its own direct preventive effect on cardiac arrhythmias [12, 13], dietary ALA also has the major advantage of never accumulating within cells and of inducing a marked shift in the endogenous metabolism of n-6 fatty acids [22]. Dietary ALA actually inhibits the elongation and desaturation of linoleic acid (18:2 n-6) into arachidonic acid [23]. Because arachidonic acid (20:4 n-6), in competition with EPA, plays an important role in inflammation (as the precursor of the proinflammatory eicosanoids and leukotrienes), modifying its amount and the amount of its fatty acid precursors almost certainly influences the prevalence and severity of eicosanoid-related disorders, including atherosclerotic complications and also SCD [22, 23]. As a matter of fact, dietary ALA has been shown to be inversely associated with the risk of fatal CHD [24]. Thus, for many authors, it is the balance between n-3 and n-6 fatty acids, rather than the absolute amounts of n-3 fatty acids in the diet, that is critical for prevention [25–27], and the importance of ALA in health and disease is now widely recognized [28, 29].

The underlying theory is that there is no major difference between the dietary and pharmacological application, and that eating fish and taking a capsule of n-3 fatty acids are basically the same thing and should be analyzed in the same way. Accordingly, whatever the way of taking n-3 fatty acids, the biological and physiological effect of the nutrient should be similar to that of the molecule. Can the GISSI trial [30] be consistently compared with the DART intervention [31]? The two trials actually provide similar clinical results but their settings were so different that the interpretation of the data may be different. In GISSI, the patients (all of whom were Italian) were advised to follow a Mediterranean diet. They did so, as shown by the fact that at the end of the trial, more that 82% of them were regularly using olive oil [30]. In addition, Marchioli and co-workers reported that those patients who most closely adopted Mediterranean dietary habits were best protected [32]. In other words, patients who did not comply with the Mediterranean diet were three times less protected than those who did [32]. However, while the exact interaction between the Mediterranean diet (or some of its characteristics) and n-3 fatty acids remains to be elucidated, the clinical effectiveness of capsules containing 0.8 g of n-3 fatty acids which was demonstrated in the GISSI trial, was actually observed in patients following a Mediterranean diet with probably a low intake in n-6 fatty acids and a large intake in oleic acid. From a practical point of view, this is very important.

What about the DART investigation? Is it simply a fish (or fish oil) trial? Whereas the trial has often been seen as an experiment testing the effect of a single factor, it is actually a trial investigating the effect of intensive dietary advice on the risk of recurrence in patients with established CHD [31]. In this trial, patients were initially seen in their homes by a nutritionist and randomized into one of three study diets in a factorial design [31]. They were visited again after one month, three months and six months, and thereafter they were contacted at three monthly intervals until two years after the entry into the trial. Those randomized to fish advice were encouraged to eat two portions of fatty fish a week and as much other fish as they could manage. Such an intensive and repeated dietary advice is obviously not just a recommendation to eat fish. When patients eat more fish (fatty fish or lean fish), they do not eat something else, presumably meat, so that they probably reduce their consumption of saturated fatty acids from terrestrial animals. Because of the associated intensive dietary advice, we can speculate that when the patients ate fish, they did not use butter and cream to prepare it, and also that they avoided some forms of preparation (deep fat fried, highly salted fish). In other words, eating more fish is almost necessarily more than a simple increase.
in the intake of n-3 fatty acids. It is also less saturated fatty acids and probably less n-6 fatty acids (those found in the vegetable oils often used to fry fish).

The same reasoning can apply to other dietary trials, for instance the Lyon Diet Heart Study [33] or the Indian Heart trial [34]. In these investigations, patients randomized into the experimental group increased their intake of n-3 fatty acids (specifically ALA in these two trials) through the consumption of foods (essentially canola oil and tree nuts) that also include potentially cardioprotective nutrients (oleic acid, alpha-tocopherol, folates, arginine, etc.) other than n-3 fatty acids. Moreover, in these trials, patients did decrease their consumption of n-6 fatty acids. It is noteworthy that in the two trials, the rates of both fatal and non-fatal CHD complications were reduced, suggesting that the protective effect of ALA is probably not restricted to a myocardial anti-arrhythmic effect as shown with the long chain n-3 fatty acids [30, 31]. In these food-based trials, however, it is quite difficult to make the difference between the health benefits resulting from n-3 fatty acids (a moderate increase), n-6 fatty acids (a decrease), from nutrients other than n-3 and n-6 fatty acids and from the interaction between the different types of nutrients. There is no room here to discuss each aspect of that complex question.

It remains, however, that we now have strong evidence that increasing the consumption of n-3 fatty acids in CHD patients results in a highly protective effect, in particular against the risk of SCD. In consequence, physicians should manage their patients so that their blood and cell concentrations in n-3 fatty acids should be high. From a practical point of view, they can advise their patients to adequately change their diet. However, in secondary prevention, cardiologists should consider as an obligation to increase the n-3 fatty acid concentrations in the blood and cell of their high risk patients. For that purpose, the systematic prescription of capsules of oils enriched in both ALA and EPA + DHA is strongly advised. This will soon be recognized as an ethical and medical obligation.

REFERENCES


